ArticleHealth science reports2026
Assessment of Awareness and Knowledge Regarding Human T-Lymphotropic Virus Type 1 (HTLV-1) Among Healthcare Workers at Imam Khomeini Hospital Complex, Tehran, in 2023-2024, A Cross-Sectional Descriptive-Analytical Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Critical Assessment of Knowledge, Attitudes, and Practices (KAP) Concerning HTLV-1 Infection Among Healthcare Professionals in Gabon.Diseases (Basel, Switzerland) · 2026Article
- Assessment of Awareness and Knowledge Regarding Human T-Lymphotropic Virus Type 1 (HTLV-1) Among Healthcare Workers at Imam Khomeini Hospital Complex, Tehran, in 2023-2024, A Cross-Sectional Descriptive-Analytical Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Human T-Lymphotropic Virus Type 1 (HTLV-1), is responsible for serious diseases such as Adult T-cell leukemia/lymphoma (ATLL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). This research aimed to explore the level of awareness and knowledge of HTLV-1 among healthcare professionals working at Imam Khomeini hospital complex in Tehran to compare their knowledge in different aspects of this virus including basic knowledge, transmission, pathogenesis, prevention and treatment. Methods: This cross-sectional, descriptive-analytical study was conducted among healthcare personnel at Imam Khomeini Hospital Complex, Tehran, during 2023-2024. Data were collected using a validated questionnaire designed to assess knowledge and attitudes about HTLV-1. The questionnaire underwent expert review for validity and reliability testing, including a 2-week test-retest process with Cohen's kappa coefficient calculation. It included demographic data, binary knowledge questions about HTLV-1 transmission, symptoms, complications, prevention, and treatment. Results: A total of 220 healthcare workers and students (63.6% female, 36.4% male) from medical, paramedical, and service fields participated in the study. Participants' attitude and knowledge levels were assessed using correct response rates, revealing significantly higher attitude scores (64.81%) compared to knowledge scores (42.61%) based on the Wilcoxon test ( Conclusion: The study highlights a notable gap in knowledge about HTLV-1 among healthcare professionals at Imam Khomeini Hospital Complex, despite relatively positive attitudes. Significant differences in knowledge were observed across age groups, with the 26-35 age group demonstrating better awareness. These findings underscore the need for targeted educational programs to improve HTLV-1 knowledge, particularly among younger and less experienced staff, to enhance preventive and diagnostic capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.